US Stock Insider Trading | Tango Therapeutics Discloses 6 Insider Transactions on February 4

K-LinePoet · 2026-02-19T03:13:33+00:00

On February 4, 2026, Tango Therapeutics disclosed multiple insider trades. Executives and directors sold tens of thousands of shares on February 3, involving millions of dollars. The company focuses on biotech research and development for cancer treatment, aiming to develop new drug targets.

K-LinePoet

2026-02-19 03:13:33

Abstract generation in progress

On February 4, 2026, Tango Therapeutics (TNGX) disclosed six insider trading transactions. Director Weber Barbara sold 30,200 shares on February 3, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 4, 2026	Executive	Beckman Daniella	February 3, 2026	Sell	113	12.90	1,457.37
February 4, 2026	Executive	Beckman Daniella	February 3, 2026	Sell	10,200	12.26	125,100.00
February 4, 2026	Executive	Crystal Adam	February 3, 2026	Sell	201	12.90	2,592.32
February 4, 2026	Executive	Crystal Adam	February 3, 2026	Sell	18,300	12.26	224,718.00
February 4, 2026	Director	Weber Barbara	February 3, 2026	Sell	333	12.90	4,294.73
February 4, 2026	Director	Weber Barbara	February 3, 2026	Sell	30,200	12.26	370,000.00
October 27, 2025	Shareholder with >10%	Third Rock Ventures IV, L.P.	October 23, 2025	Sell	474,000	10.15	4,846,600.00
September 17, 2025	Shareholder with >10%	Third Rock Ventures IV, L.P.	September 16, 2025	Sell	363,500	7.04	2,559,300.00
September 9, 2025	Shareholder with >10%	Third Rock Ventures IV, L.P.	September 8, 2025	Sell	86,500	7.04	608,600.00
September 9, 2025	Shareholder with >10%	Third Rock Ventures IV, L.P.	September 5, 2025	Sell	642,900	7.00	4,500,300.00

[Company Profile]

Tango Therapeutics Inc. was incorporated in Delaware on May 21, 2020. It is a biotechnology company dedicated to discovering new drug targets and providing next-generation precision medicine for cancer treatment. Tango employs a patient-centric approach, utilizing synthetic lethal genetic principles to discover and develop therapies targeting key cancer vulnerabilities. This includes expanding the scope of precise oncology targets into new areas, such as tumor suppressor gene loss and its contribution to cancer cell immune evasion.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes